Drug Profile
Vesatolimod - Gilead Sciences
Alternative Names: GS-9620Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Aelix Therapeutics; Gilead Sciences
- Class Amines; Antiretrovirals; Antivirals; Ethers; Pteridines; Pyrrolidines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 27 Nov 2023 Gilead Sciences terminates phase I trial in HIV-1 infections in the USA (PO) due to sponsor's decision to change the clinical development plan of this molecule (NCT05458102)
- 06 Oct 2023 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences plans a phase I/II trial in HIV 1 infection (Combination therapy,Treatment-experienced) in US and Brazil (NCT06071767)
- 19 Feb 2023 Pharmacodynamics data from a phase Ib trial in HIV infection presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)